These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25263008)

  • 21. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
    Eyre TA; Collins GP; Goldstone AH; Cwynarski K
    Br J Haematol; 2014 Aug; 166(3):336-51. PubMed ID: 24842496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC).
    Niere F; Namjoshi S; Song E; Dilly GA; Schoenhard G; Zemelman BV; Mechref Y; Raab-Graham KF
    Mol Cell Proteomics; 2016 Feb; 15(2):426-44. PubMed ID: 26419955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can We Use mTOR Inhibitors for COVID-19 Therapy?
    Aneva IY; Habtemariam S; Banach M; Sil PC; Sarkar K; Sahebnasagh A; Kamal MA; Khayatkashani M; Kashani HRK
    Comb Chem High Throughput Screen; 2022; 25(11):1805-1808. PubMed ID: 34847842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacology of mTOR inhibition.
    Guertin DA; Sabatini DM
    Sci Signal; 2009 Apr; 2(67):pe24. PubMed ID: 19383975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease.
    Leo MS; Sivamani RK
    Arch Dermatol Res; 2014 Dec; 306(10):861-71. PubMed ID: 24972910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
    Tao Z; Barker J; Shi SD; Gehring M; Sun S
    Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fisetin regulates obesity by targeting mTORC1 signaling.
    Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
    J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway.
    Chen L; Zhang Y; Li D; Zhang N; Liu R; Han B; Wei C; Liu H; Xu X; Hao J
    J Neuroimmunol; 2016 Oct; 299():164-171. PubMed ID: 27725116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of mTORC1 renders cardiac protection against lipopolysaccharide.
    Li X; Jiang L; Lin S; He Y; Shen G; Cai Z; Ling M; Ni J; Zhang H; Zhang M
    Int J Clin Exp Pathol; 2014; 7(12):8432-42. PubMed ID: 25674207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways.
    Zhang L; You J; Sidhu J; Tejpal N; Ganachari M; Skelton TS; Kloc M; Li XC; Ghobrial RM
    Transplantation; 2013 Nov; 96(9):782-90. PubMed ID: 23985719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR inhibitors as a new therapeutic option for epilepsy.
    Curatolo P; Moavero R
    Expert Rev Neurother; 2013 Jun; 13(6):627-38. PubMed ID: 23739000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammalian target of rapamycin complex 2 (mTORC2) regulates LPS-induced expression of IL-12 and IL-23 in human dendritic cells.
    Wei WC; Liu CP; Yang WC; Shyur LF; Sheu JH; Chen SS; Yang NS
    J Leukoc Biol; 2015 Jun; 97(6):1071-80. PubMed ID: 25877925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse.
    Neasta J; Barak S; Hamida SB; Ron D
    J Neurochem; 2014 Jul; 130(2):172-84. PubMed ID: 24666346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Focus Issue: demystifying mTOR signaling.
    Gough NR
    Sci Signal; 2009 Apr; 2(67):eg5. PubMed ID: 19383973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TORC2 Structure and Function.
    Gaubitz C; Prouteau M; Kusmider B; Loewith R
    Trends Biochem Sci; 2016 Jun; 41(6):532-545. PubMed ID: 27161823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.